Global HIV Clinical Trials Market Analysis (2026–2030): Strategic Insights
The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
What Is The Projected Increase In Market Value Of The Human Immunodeficiency Viruses (HIV) Clinical Trials Market During 2026–2030?
The human immunodeficiency viruses (hiv) clinical trials market has experienced substantial expansion in recent years. It is projected to grow from $1.94 billion in 2025 to $2.11 billion in 2026, at a compound annual growth rate (CAGR) of 9.2%. The market’s past growth can be attributed to factors such as the high global HIV disease burden, the broadening scope of antiretroviral drug research, increased public and private financial support for HIV investigations, advancements in clinical research infrastructure, and strong regulatory backing for HIV drug development.
The human immunodeficiency viruses (hiv) clinical trials market size is projected to experience significant expansion in the coming years. By 2030, it is forecast to reach $2.97 billion, growing at a compound annual growth rate (CAGR) of 8.9%. This increase over the forecast period can be attributed to the rising development of both curative and preventive HIV therapies, the increasing adoption of adaptive trial designs, the expansion of vaccine-focused HIV trials, the growing integration of AI in clinical research, and a heightened focus on long-term safety and efficacy outcomes. Significant trends during this period include the wider acceptance of decentralized clinical trial models, the increased use of digital patient recruitment tools, a growing emphasis on long-acting HIV therapies in trials, an expansion of real-world evidence integration, and enhanced utilization of data analytics in trial management.
Access Your Free Sample Report For In-Depth Market Analysis:
What Key Factors Are Shaping The Human Immunodeficiency Viruses (HIV) Clinical Trials Market Landscape?
The rising prevalence of human immunodeficiency virus (HIV) infections is projected to fuel the expansion of the human immunodeficiency virus (HIV) clinical trials market moving forward. Human immunodeficiency virus (HIV) infections describe a condition where the HIV virus targets and weakens the body’s immune system, making individuals more vulnerable to illnesses and potentially leading to AIDS. The surge in HIV infections is largely due to insufficient knowledge about transmission, which fosters risky behaviors and postponed testing, thereby facilitating the virus’s dissemination. Human immunodeficiency virus (HIV) clinical trials assist patients with HIV infections by evaluating novel medications, immunizations, and therapeutic approaches to enhance prevention, manage the virus more effectively, and ultimately slow disease progression and spread. For example, in August 2024, the Minority HIV/AIDS Fund (MHAF), a US-based government agency, reported that an estimated 39.9 million individuals globally were living with HIV in 2023, comprising 38.6 million adults and 1.4 million children, when compared to previous years. Consequently, the growing occurrence of human immunodeficiency virus (HIV) infections is propelling the development of the human immunodeficiency virus (HIV) clinical trials market.
How Is The Human Immunodeficiency Viruses (HIV) Clinical Trials Market Segmented Across Different Segment Categories?
The human immunodeficiency viruses (hiv) clinical trials market covered in this report is segmented –
1) By Phase: Phase I, Phase II, Phase III, Phase IV, Preclinical
2) By Drug Type: Antiretroviral Therapy (ART), Pre-Exposure Prophylaxis (PrEP), Post-Exposure Prophylaxis (PEP), Long-Acting Injectable Antiretrovirals, Experimental Drugs
3) By Study Design: Interventional Studies, Observational Studies, Expanded Access Studies
4) By Patient Population: Adults, Pediatric Patients, Seniors, Pregnant Women, High-Risk Populations
5) By End User: Pharmaceutical Companies, Research Institutes, Hospitals, Other End-Users
Subsegments:
1) By Phase I: First-In-Human Studies, Safety And Tolerability Studies
2) By Phase II: Dose-Finding Studies, Efficacy Studies
3) By Phase III: Pivotal Trials, Comparative Efficacy Studies
4) By Phase Iv: Post-Marketing Surveillance, Long-Term Safety Studies
5) By Preclinical: In Vitro Studies, Animal Studies
What Market Trends Are Affecting The Human Immunodeficiency Viruses (HIV) Clinical Trials Market?
Key players in the human immunodeficiency virus (HIV) clinical trials sector are concentrating on creating novel solutions, including HIV prevention injections, to boost treatment effectiveness and lower transmission rates. An HIV prevention injection is a long-acting injectable drug given at regular intervals to avert HIV infection in at-risk individuals by impeding the virus’s ability to establish itself in the body. As an example, in August 2025, Gilead Sciences Inc., a pharmaceutical firm based in the US, secured approval from the European Union for its drug Yeytuo (lenacapavir) for HIV treatment. This particular treatment is a twice-yearly injectable for HIV prevention, demonstrating high efficacy, almost 100% in trials, thereby substantially decreasing the chance of sexually transmitted HIV-1 infection. The long-acting dosage form enhances patient adherence and convenience when contrasted with daily oral PrEP, filling a significant void in HIV prevention strategies. Intended for adults and adolescents with elevated risk, this aims to broaden accessibility and contribute to the global reduction of new HIV infections, aligning with comprehensive prevention approaches.
Which Organizations Play A Role In The Human Immunodeficiency Viruses (HIV) Clinical Trials Market Landscape?
Major companies operating in the human immunodeficiency viruses (hiv) clinical trials market are Johnson & Johnson, F. Hoffmann-La Roche Ltd., Pfizer Inc., AbbVie Inc., Sanofi S.A., Thermo Fisher Scientific Inc., Amgen Inc., Gilead Sciences Inc., Merck & Co., IQVIA Holdings Inc., ICON plc, Moderna Inc., ViiV Healthcare Limited, HOOKIPA Pharma Inc., Excision BioTherapeutics Inc., American Gene Technologies International Inc., Bionor Holding AS, Aelix Therapeutics, Immuno Cure BioTech Private Limited, ImmunityBio
Get The Full Human Immunodeficiency Viruses (HIV) Clinical Trials Market Report:
Which Region Is The Leading Market For The Human Immunodeficiency Viruses (HIV) Clinical Trials Market?
North America was the largest region in the human immunodeficiency viruses (HIV) clinical trials market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the human immunodeficiency viruses (hiv) clinical trials market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Human Immunodeficiency Viruses (HIV) Clinical Trials Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Human Immunodeficiency Viruses (HIV) Clinical Trials Market 2026, By The Business Research Company
Virtual Clinical Trials Market Report 2026
https://www.thebusinessresearchcompany.com/report/virtual-clinical-trials-global-market-report
Hiv Drug Market Report 2026
https://www.thebusinessresearchcompany.com/report/hiv-drug-global-market-report
Antiviral Combination Therapy Market Report 2026
https://www.thebusinessresearchcompany.com/report/antiviral-combination-therapy-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
[KClientError] [REQ_ERR: OPERATION_TIMEDOUT] [KTrafficClient] Something is wrong.
